Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholders Sue To Block Roche’s|$44 Billion Buyout Of Genentech

WILMINGTON, DEL. (CN) - Genentech shareholders say Roche Holding's $43.7 billion takeover offer - $89 per share - is too low. The shareholders class action in Chancery Court claims Genentech is worth more than $100 per share.

Roche already owns 56 percent of Genentech, the world's second-largest biotechnology firms. Roche's $89 per share offer, announced Monday, was an 8.8% premium over Genentech's Friday closing price. Among Genentech's products are the cancer drugs Avastin and Herceptin.

Roche, a Swiss drug giant, paid $2.1 billion in 1990 for 60 percent of Genentech. Its holdings have decreased to 56 percent of the company since then.

Lead plaintiff, the Montgomery County Employees Retirement Fund, is represented by Chimicles & Tikellis.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...